Evidence map›Paper›PMID 38659866›Full record

ArticleResearch square2024

Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity.

Jin Wang, Dong Lu, Xin Yu, Xiaoli Qi, Hanfeng Lin, Bryan L Holloman, Feng Jin, Longyong Xu, Lang Ding, Weiyi Peng and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jin WangBaylor College of Medicine.ORCID 0000-0003-3625-7919
Dong LuBaylor College of Medicine.
Xin YuBaylor College of Medicine.
Xiaoli QiBaylor College of Medicine.
Hanfeng LinBaylor College of Medicine.ORCID 0000-0002-3172-5616
Bryan L HollomanBaylor College of Medicine.
Feng JinBaylor College of Medicine.
Longyong XuBaylor College of Medicine.
Lang DingBaylor College of Medicine.ORCID 0000-0002-5365-9445
Weiyi PengUniversity of Houston.ORCID 0000-0002-7785-6240
Meng WangJanelia Research Campus.ORCID 0000-0002-5898-6007
Xi ChenBaylor College of Medicine.ORCID 0000-0002-7995-6202
Baylor College of Medicine · USJanelia Research Campus · USUniversity of Houston · US

Funding

Development of First-in-Class RIPK1 Degraders to Improve Cancer ImmunotherapiesR01CA268518 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Jin Wang · 2022 to 2026
$3.5M
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell MalignanciesR01CA250503 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WANG, JIN, WANG, MICHAEL · 2020 to 2024
$3.4M
NCI NIH HHS R01 CA250503NCI NIH HHS R01 CA268518
6 · The paper itself

Abstract

The scaffolding function of receptor interacting protein kinase 1 (RIPK1) confers intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs) and has emerged as a promising target for improving cancer immunotherapies. To address the challenge posed by a poorly defined binding pocket within the intermediate domain, we harnessed proteolysis targeting chimera (PROTAC) technology to develop a first-in-class RIPK1 degrader, LD4172. LD4172 exhibited potent and selective RIPK1 degradation both

Identifiers

PMID38659866
PMCPMC11042424
OpenAlexW4394575241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.